Sign In
Buy GMDA
$0.0327
+0 (+0%)
At Close: Aug 27, 2024
Gamida Cell Stock Jumps Over 100% on FDA Approval
01:10pm, Tuesday, 18'th Apr 2023
Gamida Cell Ltd. (NASDAQ: GMDA) is an Israeli-based developmental biotechnology company specializing in discovering and advancing cell therapies to fight blood cancer and other illnesses.
Gamida Cell shares jump on FDA recognition of allogeneic cell therapy
12:13pm, Tuesday, 18'th Apr 2023
Gamida Cell shares shot higher on Tuesday after its allogeneic cell therapy received US Food and Drug Administration (FDA) approval. Its drug candidate Omisirge received breakthrough therapy designati
Why Is Gamida Cell (GMDA) Stock Up 48% Today?
09:26am, Tuesday, 18'th Apr 2023
Gamida Cell (NASDAQ: GMDA ) stock is taking off on Tuesday after getting an update from the FDA concerning Omisirge. Omisirge is the company's cell therapy designed to treat patients with hematologic
Promising Upsides on these Biotech Penny Stocks
08:17am, Tuesday, 18'th Apr 2023
For investors willing to do their research and take calculated risks, biotech penny stocks can offer the potential for high returns. These companies have a low market capitalization and are not yet pr
3 Hot Penny Stocks To Watch In The Stock Market Today
03:24pm, Monday, 17'th Apr 2023
Penny stocks to watch this week. The post 3 Hot Penny Stocks To Watch In The Stock Market Today appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.
Gamida Cell (GMDA) Upgraded to Buy: Here's Why
01:33pm, Monday, 16'th Jan 2023
Gamida Cell (GMDA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
Gamida Cell to Present Corporate Highlights at Multiple Upcoming Investor Conferences
08:00am, Wednesday, 23'rd Nov 2022
BOSTON--( BUSINESS WIRE )--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, toda
Gamida Cell Ltd. (GMDA)Q3 2022 Earnings Call Transcript
11:08am, Monday, 14'th Nov 2022
Gamida Cell Ltd. (NASDAQ:GMDA ) Q3 2022 Results Conference Call November 14, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Abigail Jenkins - Presid
Gamida Cell to Present Corporate Highlights at 2022 Cell & Gene Meeting on the Mesa
07:00am, Monday, 10'th Oct 2022
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease
Gamida Cell Ltd. (GMDA) CEO Julian Adams on Q2 2022 Results - Earnings Call Transcript
01:54pm, Monday, 15'th Aug 2022
Gamida Cell Ltd. (NASDAQ:GMDA ) Q2 2022 Earnings Conference Call August 15, 2022 8:00 AM ET Company Participants Heather DiVecchia - Director of IR & Corporate Communications Julian Adams - CEO Ronit
Gamida Cell to Present Corporate Highlights at the Jefferies Healthcare Conference
04:30pm, Wednesday, 01'st Jun 2022
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapy candidates for patients with hematologic and solid cancers and other serious disease
Gamida Cell to Present Corporate Highlights at the H.C. Wainwright Global Life Sciences Conference
04:30pm, Tuesday, 17'th May 2022
BOSTON--(BUSINESS WIRE)--Gamida Cell Ltd. (Nasdaq: GMDA), the leader in the development of NAM-enabled cell therapies for patients with hematologic and solid cancers and other serious diseases, today
Gamida Cell Ltd. (GMDA) Management on Q1 2022 Results - Earnings Call Transcript
11:26am, Tuesday, 10'th May 2022
Gamida Cell Ltd. (NASDAQ:GMDA ) Q1 2022 Results Conference Call May 10, 2022 8:00 AM ET Company Participants Heather DiVecchia - Chief of Staff Michele Korfin - Chief Operating Officer and Chief Comme
Gamida Cell Posts Updated Omidubicel Data In Blood Cancer Patients
12:41pm, Wednesday, 27'th Apr 2022
Gamida Cell Ltd (NASDAQ: GMDA) announced that updated infection data on omidubicel compared to umbilical cord blood transplantation (UCB) was shared at the Transplantation & Cellular Therapy ASTCT
Gamida Cell Shares Jump On FDA Nod To Cell Therapy Trial In Blood Cancer Settings
09:33am, Tuesday, 26'th Apr 2022
The FDA has signed off and removed the clinical hold for a cryopreserved formulation of Gamida Cell Ltd's (NASDAQ: GMDA) GDA-201, an off-the-shelf cell therapy candidate for follicular and diffuse
